Clinical Trial Update: Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating carfilzomib in multiple myeloma that relapsed after high-dose melphalan with autologous stem cell support.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Carfilzomib (carfilzomib)

Snippet

Sponsor: Henrik Gregersen | Conditions: Multiple Myeloma | Phase 2 | Status: UNKNOWN